Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign
TORONTO, Oct. 9, 2013 /PRNewswire/ - WaveCheck - a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation - is poised to transform chemotherapy response monitoring for women with breast cancer.
WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.
Developed by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook's Odette Cancer Centre, and Michael C. Kolios, professor of Physics and Canada Research Chair in Biomedical Applications of Ultrasound at Ryerson, WaveCheck has been used in clinical studies with nearly 100 women receiving upfront, neoadjuvant chemotherapy to treat locally-advanced breast cancer. These results are published in two leading journals, Clinical Cancer Research and Translational Oncology.
Watch Czarnota, Kolios and three of the 100 women who participated in the first Sunnybrook study explain WaveCheck's impact in the Indiegogo campaign video.
"The hard truth for women with breast cancer is that 60 to 70 per cent of chemotherapy treatments fail," said Czarnota, who is also a senior scientist and director of cancer research at Sunnybrook Research Institute. "The 1.5 million women worldwide who will be diagnosed with breast cancer this year need to know that their chemotherapy is working as soon as possible. But this kind of treatment monitoring doesn't currently exist in standard clinical practice. Instead, a woman's tumour response is evaluated after she completes her chemotherapy treatment, which is typically a four- to six-month process.
"We believe that fast access to WaveCheck's analysis could give women and their medical teams crucial insight into whether they've chosen an effective treatment much sooner and, eventually, give insight into whether to change her treatment if her tumour's not responding."
WaveCheck's key benefits:
To make WaveCheck available to women everywhere as fast as possible, MaRS Innovation seeks to raise $96,987 on Indiegogo from October 9 to November 27, 2013 and get the first of three North American clinical study locations running in parallel with Sunnybrook's existing data. The campaign's overall goal is to raise $687,950 to fund all three sites with WaveCheck's partners at Princess Margaret Hospital in Toronto, Canada; London Health Sciences Centre in London, Canada; and MD Anderson Cancer Center in Houston, U.S.A.
"WaveCheck is in the last development stage in its journey from the laboratory to the clinic, which is also where funding becomes hardest to find," said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. "As WaveCheck's commercialization agent, we provided $250,000 in seed funds along with business development and intellectual property protection to bring WaveCheck this far; it's cleared the proof-of-principle and prototyping phases with flying colours. But successfully completing these parallel studies is crucial in proving WaveCheck's data is replicable in any clinic, convincing other doctors to eventually adopt the technique, and accelerating the time it takes to bring it to clinics worldwide."
"Sunnybrook was joined by many funding agencies and foundations to invest in the research underlying WaveCheck at much earlier stages," said Dr. Michael Julius, vice-president, research, Sunnybrook Health Sciences Centre. "This investment underscores that transformative research must be supported at all stages along the innovation pipeline if we are to get it to those who need it."
Supporting agencies include the Canada Foundation for Innovation (CFI), Canadian Institutes of Health Research (CIHR), Federal Economic Development Agency for Southern Ontario, the Ontario Ministry of Research and Innovation, Natural Sciences and Engineering Research Council (NSERC) and the Terry Fox Foundation. Kolios holds a Canada Research Chair; Czarnota holds a Research Chair in Experimental Therapeutics and Imaging from Cancer Care Ontario.
"Sunnybrook and MaRS Innovation are building on this incredible support by earmarking an additional $75,000 for that first study site, which will be matched by the Indiegogo campaign donations," said Julius. "Together, we can help more women with breast cancer faster."
"If these clinical studies replicate the early studies, we could use this technology to monitor tumor response early in treatment and to predict which patients will continue on in their therapy to have a complete pathological response," said Wei Yang, M.D., professor of Diagnostic Imaging at The University of Texas MD Anderson Cancer Center and clinician lead at the designated WaveCheck study site. "On the other hand, for patients in whom the test indicates a poor response to treatment, the regimen could be changed to a more efficacious one."
WaveCheck's Indiegogo campaign has received generous support from 12 artists across Canada and internationally, worth a combined total of over $15,000:
For more information about WaveCheck's vibrant artistic support, see the Artists' Profiles on WaveCheck.ca. A FAQ is also available along with additional background, technical details and photos: wavecheck.ca.
SOURCE MaRS Innovation
Image with caption: "WaveCheck Inventors and long-time research partners Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre (left) and Professor Michael C. Kolios of Ryerson University. (CNW Group/MaRS Innovation)". Image available at: http://photos.newswire.ca/images/download/20131009_C8429_PHOTO_EN_31881.jpg
Image with caption: "WaveCheck comparison image: Yellow indicates where tumour tissue is responding to chemotherapy; red indicates no chemotherapy response. (CNW Group/MaRS Innovation)". Image available at: http://photos.newswire.ca/images/download/20131009_C8429_PHOTO_EN_31880.jpg
©2012 PR Newswire. All Rights Reserved.